GH Research (GHRS) Total Non-Current Liabilities (2023 - 2025)
GH Research (GHRS) recorded quarterly Total Non-Current Liabilities of $147000.0 in Q4 2025, down 32.26% quarter-over-quarter from $217000.0 in Q3 2025, and down 60.16% on a YoY basis from $369000.0 in Q4 2024.
GH Research (GHRS) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
GH Research's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $147000.0 for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 60.16% year-over-year to $147000.0; the TTM figure through Dec 2025 stood at $147000.0 (down 60.16% YoY), while the FY2025 annual figure was $147000.0, down 60.16% from the prior year.
- Total Non-Current Liabilities was $147000.0 for Q4 2025 at GH Research, down from $217000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $791000.0 in Q1 2023 to a low of $147000.0 in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $472416.7 across 3 years, with a median of $477500.0 in 2024.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities retreated 29.08% in 2024, then tumbled 60.16% in 2025.
- A 3-year view of Total Non-Current Liabilities shows it stood at $631000.0 in 2023, then slumped by 41.52% to $369000.0 in 2024, then tumbled by 60.16% to $147000.0 in 2025.
- The last three Total Non-Current Liabilities figures came in at $147000.0 (Q4 2025), $217000.0 (Q3 2025), and $283000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 42,980.09 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 64.76 Mn |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | 147,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 147,000.00 |
| Sep 30, 2025 | 217,000.00 |
| Jun 30, 2025 | 283,000.00 |
| Mar 31, 2025 | 322,000.00 |
| Dec 31, 2024 | 369,000.00 |
| Sep 30, 2024 | 458,000.00 |
| Jun 30, 2024 | 497,000.00 |
| Mar 31, 2024 | 561,000.00 |
| Dec 31, 2023 | 631,000.00 |
| Sep 30, 2023 | 661,000.00 |
| Jun 30, 2023 | 732,000.00 |
| Mar 31, 2023 | 791,000.00 |